Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia
Multi-center, international trial targets significant unmet need for which no treatments are approved
Approximately 500 patients to be enrolled at 60 clinical sites in U.S. and Europe
WALTHAM, Mass., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the screening of the first patient in the pivotal Phase 3 clinical trial of MIN-101 (Study MIN-101C07) as monotherapy for negative symptoms in patients diagnosed with schizophrenia.
The trial is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, 12-week study to evaluate the efficacy and safety of 32 milligrams (mg) and 64 mg of MIN-101 in adult patients with negative symptoms of schizophrenia. The 12-week study will be followed by a 40-week, open-label extension period during which patients on drug will continue receiving their original dose and patients on placebo will receive either 32 mg or 64 mg of MIN-101.
"The initiation of this pivotal Phase 3 trial is an important milestone for Minerva," said Dr. Remy Luthringer, chief executive officer of Minerva. "Patients with schizophrenia lack a treatment directed specifically toward negative symptoms, the key unmet need for these patients, which also helps stabilize positive symptoms. As no treatments are approved for negative symptoms, we believe this trial represents an exciting opportunity to make a significant impact on the therapeutic landscape for a debilitating disease affecting millions of patients in the U.S. and the rest of the world.
"Following discussion with the U.S. Food and Drug Administration (FDA) on the study's design and operational conduct, we are employing the same doses in monotherapy as used in the successful Phase 2b trial, as well as the same primary endpoint following the 12-week double-blind treatment period and the same patient recruitment criteria," said Dr. Luthringer. "We are looking forward to working with our investigators in the U.S. and Europe in the months ahead."
Approximately 500 patients will be enrolled at approximately 60 clinical sites in the U.S. and Europe, with about 30 percent of patients coming from the U.S. Patients will be initially randomized equally to receive one of the two doses of MIN-101 or placebo for 12 weeks. Thereafter, all patients will continue treatment with active drug for an additional 40 weeks, during which patients initially randomized to the two treatment groups will continue treatment with the same doses, while patients initially randomized to placebo will cross over to one of the two doses. Top-line results from the 12-week double blind phase of this trial are expected in the first half of 2019.
The primary endpoint of this trial will be improvement in negative symptoms in patients treated with MIN-101 compared to placebo as measured by the change in the Positive and Negative Syndrome Scale (PANSS) Marder negative symptoms factor score (NSFS) over the 12-week double-blind treatment period. The key secondary endpoint will be the effect of MIN-101 compared to placebo as measured by the Personal and Social Performance (PSP) total score over the same period. Additional secondary endpoints will be the effect of MIN-101 compared to placebo on the Clinical Global Impression of Severity (CGI-S) score and safety and tolerability.
Patients admitted into the trial must have a documented diagnosis of schizophrenia for at least one year and be symptomatically stable for at least 6 months with moderate to severe negative symptoms (>20 on the PANSS negative symptom subscale) and stable positive symptoms. Patients without severe symptoms of suspiciousness, agitation, hostility, uncooperativeness or impulsivity will be recruited. These eligibility criteria are believed to represent the real-world patient population who may benefit when the drug is used in clinical practice1. In addition, patients treated with psychotropic agents will need to undergo wash-out before receiving study drug. These parameters were applied in screening the population treated in the Phase 2b trial.
MIN-101 is a drug candidate with equipotent affinities for sigma 2 and 5-hydroxytryptamine-2A (5-HT2A) and at lower affinity levels, A1-adrenergic receptors. MIN-101 exhibits very low or no affinity for dopaminergic, muscarinic, cholinergic and histaminergic receptors. MIN-101 has no direct dopaminergic post-synaptic blocking effects, known to be involved in some side effects like extrapyramidal symptoms, sedation, prolactin increases and weight gain.
As described by the National Institute of Mental Health, schizophrenia is a chronic and severe disorder that affects how a person thinks, feels and acts2. The disease affects more than 21 million people worldwide, according to the World Health Organization3. Schizophrenic patients suffer from positive, negative and cognitive symptoms. Negative symptoms are disruptions to normal emotions and behaviors that may signal social withdrawal. Patients may be socially inhibited, lack the ability to begin and sustain planned activities, or speak little even when forced to interact. Negative symptoms account for a substantial portion of the morbidity associated with schizophrenia4. They persist chronically throughout an individual patient's lifetime and increase with severity over time.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in clinical development for schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and major depressive disorder (MDD); MIN-117, in clinical development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and results of future clinical milestones with MIN-101, including the planned Phase 3 trial of MIN-101, the timing and scope of future clinical trials and results of clinical trials with this compound; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; the Company's ability to successfully develop and commercialize MIN-101; the sufficiency of the Company's current cash position to fund operations; and management's ability to successfully achieve its goals. These forward-looking statements are based on the Company's current expectations and may differ materially from actual results due to a variety of factors including, without limitation, whether MIN-101 will advance further in the clinical trials process; management's ability to successfully achieve its goals; its ability to raise additional capital to fund operations on acceptable terms; and general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in the Company's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, filed with the Securities and Exchange Commission on November 6, 2017. Copies of reports filed with the SEC are posted on the Company's website at www.minervaneurosciences.com . The forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements, except as required by law.
1 Dunayevich, E., Chen, C.Y., Marder, S.R., and Rabinowitz, J. (2014). Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: An analysis of the CATIE dataset. Eur. Neuropsychopharmacol. 24 (10),1615-1621.
4 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, American Psychiatric Association.
Contact:William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
eGain to exhibit at Call Centre World 2018 in Berlin23.1.2018 12:30 | Pressemelding
Company will join forces with Cisco to showcase knowledge-infused, AI-guided omnichannel customer engagement at Europe's premier call centre conference SUNNYVALE, Calif. and NEWBURY, U.K., Jan. 23, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud customer engagement solutions, today announced that the company will showcase its award-winning digital engagement suite for the Cisco contact centre infrastructure-eGain Solve(TM) for Cisco Unified CCE(TM)-at CCW 2018 in Berlin, scheduled for February 26th through March 1st , 2018. Proven in world-class deployments, eGain Solve suite helps companies simultaneously elevate the customer experience (CX), business experience (BX), and agent experience (AX) to make digital transformation of experiences (DX) easy and successful. The solution dramatically improves metrics such as NPS (Net Promoter Score), CSAT (Customer Satisfaction), FCR (First-Contact Resolution), AHT (Average Handle Time), speed to agent competency, tra
Quinta do Lago: A resort that delivers year-round ROI23.1.2018 12:10 | Pressemelding
LONDON, Jan. 23, 2018 (GLOBE NEWSWIRE) -- A holiday home is not only somewhere to create treasured memories with family and friends, it can also represent a solid business investment. Accessibility, amenities, seasonal consistency and security are all likely to be key considerations when searching for a potential location, and Quinta do Lago scores highly across the board. Located just to the west of Faro Airport, the picturesque resort is part of the Algarve's Golden Triangle and easily accessible from most UK airports, as well as major European cities such as Paris, Madrid and Frankfurt. Accessibility is essential if holiday homes are to provide year-round return on investment (ROI), and Quinta do Lago is capable of attracting weekend holidaymakers and longer-term travellers alike. Fantastic leisure facilities ensure that the resort delivers year-round appeal. Golf, wellness services, award-winning restaurants and a multi-sports hub provide Quinta do Lago with seasonal consistency. F
AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia23.1.2018 04:44 | Pressemelding
TOKYO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- AnGes, Inc., a biopharmaceutical company focused on developing innovative gene-based medicines for serious diseases, announced today the submission of an application for marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for HGF plasmid, an investigational gene therapy for the treatment of critical limb ischemia (CLI), the most severe condition of peripheral arterial disease. The submission is based on the positive results from the randomized, placebo-controlled phase 3 trial and investigator-led clinical study conducted in Japan. AnGes anticipates being granted conditional approval under the regulatory scheme of "Approval with Conditions and Time Limit" for regenerative medicines. The review process is expected to take approximately one year. HGF plasmid has the potential to be one of the first gene therapy products to be approved for a non-genetic disease with chronic conditions. AnGes grants to Mitsubishi Tan
SEMAFO Inc. : Q4 and Annual 2017 Production and Costs in Line23.1.2018 00:59 | Pressemelding
Boungou 80% Complete - Continues on Time, on Budget MONTREAL, Jan. 22, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports 2017 production of 206,400 ounces at an all-in sustaining cost of $943 per ounce. As a result, the Corporation has beat its revised production and met its cost guidance for the year. Mana In the fourth quarter, Mana produced 49,500 ounces of gold at a total cash cost1 of $667 per ounce and all-in sustaining cost2 of $987 per ounce Annual production of 206,400 ounces, slightly ahead of 2017 guidance of 190,000 to 205,000 ounces Total cash cost1 for 2017 of $655 per ounce All-in sustaining cost2 for 2017 of $943 per ounce, in line with guidance of $920 to $960 per ounce Gold sales of 205,300 ounces generated 2017 revenues of $259 million ($1,261 per ounce) Mining Operations Mana, Burkina Faso Three-month period Year ended December 31, ended December 31, 2017 2016 Variation 2017 2016 Variation Tonnes processed 653,500 714,200 (8%) 2,739,900 2,753,300 - He
Atico Reports 2017 Fourth Quarter and Full Year Production Results22.1.2018 22:30 | Pressemelding
VANCOUVER, British Columbia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSXV:ATY) (OTC:ATCMF) is pleased to announce operating results for the three and twelve month periods ended December 31, 2017 from its El Roble mine. Production totaled 5.33 million pounds of copper with 2,972 ounces of gold for the fourth quarter ("Q4 2017") and 20.63 million pounds of copper with 10,923 ounces of gold in concentrates for the full year 2017. "Atico has successfully concluded its fourth full year of operating the El Roble mine, exceeding 2017 guidance while achieving the highest annual production results to date," said Fernando E. Ganoza, CEO. "In the upcoming year, we will focus on increasing mineral resources through aggressive exploration at the El Roble mine and the surrounding prospective 6,600 hectare land package, to continue growing production and expanding the operation." Fourth Quarter and Full Year Operational Highlights Fourth Quarter Producti
Banque Fédérative du Credit Mutuel: Post Stabilisation Notice22.1.2018 18:54 | Pressemelding
PARIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Banque Fédérative du Credit Mutuel Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: Banque Fédérative du Credit Mutuel Guarantor (if any): na Aggregate nominal amount: GBP 450,000,000 Description: 1.375% due Dec 2021 Offer price: 99.872 Stabilising Managers: HSBC & Goldman Sachs This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS The company news service from the London Stock Exchange Contacts: RNS Customer Services 0044-207797-4400 firstname.lastname@example.org http://www.rns.com This announ
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom